Efficacy and safety of subantimicrobial dose, modified-release doxycycline 40 mg versus doxycycline 100 mg versus placebo for the treatment of inflammatory lesions in Moderate and Severe Acne: A Randomized, Double-Blinded, Controlled Study

Journal of Drugs in Dermatology

Volumn 14, Issue 6, 2015, Pages 581-586

  Moore, Angela ^a   Ling, Mark ^b,c   Bucko, Alicia ^d   Manna, Vasant ^e   Rueda, Marie Jose ^f  

^a Medical Center of Arlington   (United States)

^b BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^c MedaPhase Inc ^*  (United States)

^d Academic Dermatology Associates   (United States)

^e Galderma R and D Inc   (United States)

^f LP   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXYCYCLINE; PLACEBO; ANTIINFECTIVE AGENT; DELAYED RELEASE FORMULATION;

ABDOMINAL DISCOMFORT; ACNE VULGARIS; ADOLESCENT; ADULT; ADVERSE OUTCOME; ARTICLE; CHILD; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG RELEASE; DRUG SAFETY; FEMALE; HEADACHE; HUMAN; INCIDENCE; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MICROCAPSULE; NAUSEA; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TABLET; URTICARIA; VOMITING; AGED; CLINICAL TRIAL; COMPARATIVE STUDY; DELAYED RELEASE FORMULATION; MIDDLE AGED; MULTICENTER STUDY; TREATMENT OUTCOME; YOUNG ADULT;

ACNE VULGARIS; ADOLESCENT; ADULT; AGED; ANTI-INFECTIVE AGENTS; CHILD; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; DOXYCYCLINE; FEMALE; HUMANS; MALE; MIDDLE AGED; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84930803385     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Thiboutot D, Gollnick H, Bettoli V., et al. New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne group. J Am Acad Dermatol. 2009; 60:S1-50.
2. Bhate K, Williams HC. Epidemiology of acne vulgaris. Br J Dermatol. 2013; 168:474-85.
3. Rademaker M, Garioch JJ, Simpson NB. Acne in schoolchildren: no longer a concern for dermatologists. Br Med J. 1989; 298:1217-1219.
4. Law MP, Chuh AA, Lee A, Molinari N. Acne prevalence and beyond: acne disability and its predictive factors among Chinese late adolescents in Hong Kong. Clin Exp Dermatol. 2010; 35:16-21.
5. Yahya H. Acne vulgaris in Nigerian adolescents - prevalence, severity, beliefs, perceptions, and practices. Int J Dermatol. 2009; 48:498-505.
6. Collier CN, Harper JC, Cafardi J.A., et al. The prevalence of acne in adults 20 years and older. J Am Acad Dermatol. 2008; 58:56-59.
7. Williams HC, Dellavalle R P, Garner S. Acne vulgaris. Lancet. 2012; 379:361-372.
8. Degitz K, Placzek M, Borelli C., Plewig G. Pathophysiology of acne. J Dtsch Dermatol Ges. 2007; 5:316-323.
9. Bikowski JB. Subantimicrobial dose doxycycline for acne and rosacea. Skinmed. 2003; 2:234-245.
10. Nguyen F, Starosta AL, Arenz S, et al. Tetracycline antibiotics and resistance mechanisms. Biol Chem. 2014; 395:559-575.
11. Data on file. Galderma Laboratories, L.P.
12. Weinberg JM. The anti-inflammatory effects of tetracyclines. Cutis. 2005; 75:6-11.
13. Sanchez J, Somolinos AL, Almodóvar PI, et al. A randomized, double-blind, placebo-controlled trial of the combined effect of doxycycline hyclate 20-mg tablets and metronidazole 0.75% topical lotion in the treatment of rosacea. J Am Acad Dermatol. 2005; 53:791-797
14. Theobald K, Bradshaw M, Leyden J. Anti-inflammatory dose doxycycline (40 mg controlled-release) confers maximum anti-inflammatory efficacy in rosacea. Skinmed. 2007; 6:221-226.
15. Fowler JF Jr. Combined effect of anti-inflammatory dose doxycycline (40-mg doxycycline, usp monohydrate controlled-release capsules) and metronidazole topical gel 1% in the treatment of rosacea. J Drugs Dermatol 2007; 6:641-645.
16. Del Rosso JQ, Webster GF, Jackson M, et al. Two randomized phase III clinical trials evaluating anti-inflammatory dose doxycycline (40-mg doxycycline, USP capsules) administered once daily for treatment of rosacea. J Am Acad Dermatol. 2007; 56:791-802.
17. Del Rosso JQ, Schlessinger J, Werschler P. Comparison of anti-inflammatory dose doxycycline versus doxycycline 100 mg in the treatment of rosacea. J Drugs Dermatol. 2008; 7:573-6.
18. Korting HC, Schöllmann C. Current topical and systemic approaches to treatment of rosacea. J Eur Acad Dermatol Venereol. 2009; 23:876-882.
19. Alikhan A, Kurek L, Feldman SR. The role of tetracyclines in rosacea. Am J Clin Dermatol. 2010; 11:79-87
20. Skidmore, R. Effects of subantimicrobial-dose doxycycline in the treatment of moderate acne. Arch Dermatol. 2003; 139:459-464.
21. Miller ST, Stevermer JJ. Low-dose doxycycline moderately effective for acne. J Fam Pract. 2003; 52:594-597
22. Parish LC, Parish JL, Routh H.B., Witkowski JA. The treatment of acne vulgaris with low dosage doxycycline. Acta Dermatovenerol Croat. 2005; 13:156-159.
23. Toossi P Farshchian M, Malekzad F, et al. Subantimicrobial-dose doxycycline in the treatment of moderate facial acne. J Drugs Dermatol. 2008; 7:1149-1152.
24. Oracea® (Doxycycline, USP) Capsules 40 mg (30 mg Immediate Release & 10. mg Delayed Release Beads) [package insert]. Fort Worth, TX, USA: Galdermao Laboratories; 2008
25. World Health Organization (WHO). 2012. The evolving threa of antimicrobial resistance: Options for action. Accessed 20 December 2013. Available at http://whqlibdoc.who.int/publications/2012/9789241503181-eng.pdf. Accessed May 16 2014
26. Rosen T. Antibiotic resistance: an editorial review with recommendations. J Drugsp Dermatol. 2011; 10:724-733.